Allergies such as asthma, eczema and hay fever could be snuffed out within five years thanks to pioneering work at The University of Manchester.
Researchers, working with colleagues at St George’s, University of London, are developing drugs designed to stop allergens from entering the body, so rendering them harmless.
Professor David Garrod said the research – recently shortlisted for the Northwest Regional Development Agency’s Bionow Project of the Year – takes a completely new approach to the treatment and prevention of allergies.
“The technology is based on our earlier discovery of how allergens, the substances that cause allergy, enter the body through the surface layer of cells that protect the skin and the tubes of the lungs,” he said.
“Allergens from pollen or house dust mites are inhaled and then dissolve the binding material between the cells that form these protective linings; they can then enter the body by passing between the cells to cause an allergic response.
“The drugs we are developing – called Allergen Delivery Inhibitors (ADIs) – are designed to disable these allergens so they can no longer eat through the protective cell layer and block the allergic reaction before it occurs.
“The effect will be like avoiding allergens altogether. Removing carpets and rigorous cleaning of homes are established ways to avoid allergens, but they are only partially effective because their effects do not ‘travel’ with allergy sufferers.
“ADIs promise to be significantly better because taking a medicine is easier than rigorous housework and pills are portable.”
Professor Garrod, who is based within Manchester’s Faculty of Life Sciences, said work on the first ADI chemical was well advanced and potential drugs could enter clinical trials as early as 2010.
If successful, the drug would treat established symptoms already found in adult sufferers and, in due course, could be used to prevent allergies in children.
“Prevention of allergies has never before been possible,” said Professor Garrod. “Current medicines don’t act against the allergen at this early stage – they only ease the symptoms – so the development of these ADIs would be a major breakthrough in our fight against allergies.”
The study has already received nearly £450,000 from the Wellcome Trust but up to £3 million will be needed to develop the drugs to the clinical-trials stage.
Professor Garrod is now seeking investment to take the research to the next stage of development and a potential $26 billion market.
Source: University of Manchester
Related stories:
Munich researchers discover key allergy gene
Together with colleagues from the Department of Dermatology and Allergy and the Center for Allergy and Environment of the Technische Universität München, scientists at the Helmholtz Zentrum München have pinpointed a major gene for allergic diseases. The gene was localized using cutting edge technologies for examining the whole human genome at the Helmholtz Zentrum München.
Novel study finds proton channels inhibit the release of histamine during allergic reactions
Inhibiting the proton currents in basophils, a rare type of white blood cell, can stop the release of histamine and could provide a new target for allergy and asthma drugs according to a new study by researchers at Rush University Medical Center in Chicago and the Johns Hopkins Asthma and Allergy Center in Baltimore. The research is published in the August 5th issue the
Proceedings of the National Academy of Sciences.
Latest research on allergies: Specific immunotherapy can help
The German Institute for Quality and Efficiency in Health Care has assessed recent evidence on allergies. It found that the once controversial immune therapy against allergy symptoms can definitely help many people with allergies.
Immune system pathway identified to fight allergens, asthma
For the first time, researchers from the University of Pittsburgh School of Medicine have identified genetic components of dendritic cells that are key to asthma and allergy-related immune response malfunction. Targeting these elements could result in more effective drugs to treat allergic disorders and asthma, according to a study reported in the May edition of the journal
Nature Medicine.
Immune system kick-started in moist nasal lining in sinusitis, asthma and colds
Scientists at Johns Hopkins have outlined a new path for potential therapies to combat inflammation associated with sinusitis and asthma based on a new understanding of the body’s earliest immune response in the nose and sinus cavities.
Allergic response tied to lipid molecules in cell membrane
A team of Penn State University researchers is the first to demonstrate that lipid molecules in cell membranes participate in mammals' reactions to allergens in a living cell. The finding will help scientists better understand how allergy symptoms are triggered, and could contribute to the creation of improved drugs to treat them. The work will be reported in the 14 March issue of the
Journal of Biological Chemistry.
Scientists move closer to developing a new class of asthma and allergy drugs
A team of Biotechnology and Biological Sciences Research Council (BBSRC) funded scientists has moved a step closer to developing a new class of effective asthma and allergy drugs. With new research published today in
The Journal of Immunology, the team from Barts and The London School of Medicine and Dentistry has found an important target that holds significant promise for millions of people suffering from allergies, asthma, rheumatoid arthritis and a range of other inflammatory diseases. This work confirms that a key component of the body's own response to allergy-causing agents (allergens) can be targeted to reduce allergic reactions in mice.
HATS off to combat asthma
Two University of Nottingham studies exploring the causes and treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD) could lead to the development of drugs to battle these debilitating conditions.